News | March 20, 2025
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Overall investment in the US facility is estimated around US$50 million
ANVIMO will be available in dosages of 240 mg and 480 mg
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The Alathur facility specializes in the production of Cephalosporin antibiotics
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Subscribe To Our Newsletter & Stay Updated
